BACKGROUND: To investigate the long-term effectiveness of intravitreal bevacizumab treatment in eyes with perfused macular edema due to branch retinal vein occlusion (BRVO). METHODS: In this prospective interventional case series, 23 consecutive, previously untreated eyes with perfused macular edema were treated with intravitreal bevacizumab (1.25 mg) injections and followed for 1 year. The main outcome measures were visual acuity (VA) and central retinal thickness (CRT). In addition, VA data were adapted to the non-logarithmic VA charts used in the previously published grid laser photocoagulation BRVO Study. RESULTS: The median VA gained 3.0 lines from baseline at 48 weeks. This was accompanied by a significant decrease of 39% of the median CRT. The mean number of re-injections was 1.6 during the first 6 months of follow-up and only 0.8 during the subsequent 6 months. In 65% of the cases, adapted VA data showed a gain of 1 or more lines and no eye lost more than 1 line. CONCLUSIONS: Repetitive intravitreal bevacizumab injections result in a significant long-term improvement of VA and CRT. The number of re-injections necessary to maintain this effect declined over time. However, the treatment seems to be only slightly better than grid laser photocoagulation.
BACKGROUND: To investigate the long-term effectiveness of intravitreal bevacizumab treatment in eyes with perfused macular edema due to branch retinal vein occlusion (BRVO). METHODS: In this prospective interventional case series, 23 consecutive, previously untreated eyes with perfused macular edema were treated with intravitreal bevacizumab (1.25 mg) injections and followed for 1 year. The main outcome measures were visual acuity (VA) and central retinal thickness (CRT). In addition, VA data were adapted to the non-logarithmic VA charts used in the previously published grid laser photocoagulation BRVO Study. RESULTS: The median VA gained 3.0 lines from baseline at 48 weeks. This was accompanied by a significant decrease of 39% of the median CRT. The mean number of re-injections was 1.6 during the first 6 months of follow-up and only 0.8 during the subsequent 6 months. In 65% of the cases, adapted VA data showed a gain of 1 or more lines and no eye lost more than 1 line. CONCLUSIONS: Repetitive intravitreal bevacizumab injections result in a significant long-term improvement of VA and CRT. The number of re-injections necessary to maintain this effect declined over time. However, the treatment seems to be only slightly better than grid laser photocoagulation.
Authors: Osman Cekiç; Stanley Chang; Joseph J Tseng; Gaetano R Barile; Lucian V Del Priore; Harold Weissman; William M Schiff; Michael D Ober Journal: Retina Date: 2005 Oct-Nov Impact factor: 4.256
Authors: G B Jaissle; F Ziemssen; K Petermeier; P Szurman; M Ladewig; F Gelisken; M Völker; F G Holz; K U Bartz-Schmidt Journal: Ophthalmologe Date: 2006-06 Impact factor: 1.059
Authors: M Bolz; M Ritter; K Polak; C Ahlers; C Hirn; C Prünte; I Golbaz; T Benesch; U Schmidt-Erfurth Journal: Ophthalmologe Date: 2008-07 Impact factor: 1.059
Authors: T C Kreutzer; C S Alge; A H Wolf; D Kook; J Burger; R Strauss; C Kunze; C Haritoglou; A Kampik; S Priglinger Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: K Kriechbaum; S Michels; F Prager; M Georgopoulos; M Funk; W Geitzenauer; U Schmidt-Erfurth Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: Melvin D Rabena; Dante J Pieramici; Alessandro A Castellarin; Ma'an A Nasir; Robert L Avery Journal: Retina Date: 2007 Apr-May Impact factor: 4.256
Authors: Alex Yuan; Baseer U Ahmad; David Xu; Rishi P Singh; Peter K Kaiser; Daniel F Martin; Jonathan E Sears; Andrew P Schachat; Justis P Ehlers Journal: Int J Ophthalmol Date: 2014-02-18 Impact factor: 1.779
Authors: Alexandra E Hoeh; Thomas Ach; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar Journal: Graefes Arch Clin Exp Ophthalmol Date: 2009-07-26 Impact factor: 3.117